If this trial is representative of R327's usefulness, an expansion to other test sites ought to lead to comparable results that would indicate excellent efficacy for R327. In a market that sees a cost to even the US healthcare system alone of US$9-13B per year, can you imagine what a new drug that 'cures' DFI like these within a couple of weeks of topical treatment is going to be worth to the company in revenues?
If this trial is representative of R327's usefulness, an...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 32.8¢ | 29.0¢ | $78.39K | 251.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 916 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 114230 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |